Literature DB >> 15114271

Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients.

Vincent Launay-Vacher1, Hassane Izzedine, Jean-Baptiste Rey, Olivier Rixe, Sophie Chapalain, Souraya Nourdine, Angelo Paci, Philippe Bourget, Gilbert Deray.   

Abstract

BACKGROUND: Chronic renal failure is a common pathology. The high frequency of this disease in the general US population has been assessed in the NHANES III study. However, the frequency of chronic renal insufficiency among cancer patients remains unclear. MATERIAL/
METHODS: 316 cancer patients were in a one-month study, included regardless of their pathology, treatment (antineoplastic drugs used or programmed to be used, pretreated, or no treatment), or any other criteria.
RESULTS: Among the patients, 287 (90.8%) had normal serum creatinine levels (<110 micromol/l), i.e. a frequency of 9.2% for renal insufficiency in our population. However, when renal function was estimated by calculating creatinine clearance using the Cockcroft and Gault formula, 33% of the patients had an estimated GFR of less than 80 ml/min. Among these, 28% had a creatinine clearance ranging form 80 to 50 ml/min and 5% had a creatinine clearance of less than 50 ml/min. Renal insufficiency is frequent in cancer patients since almost one third of the patients present renal insufficiency. Furthermore, among patients with normal serum creatinine levels, one patient out of five has asymptomatic renal insufficiency.
CONCLUSIONS: Therefore, it is of major importance that renal function be assessed by calculation of creatinine clearance using the Cockcroft and Gault formula in every patient, even when serum creatinine is within the normal range.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15114271

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  14 in total

1.  Accuracy of GFR estimation by the Cockroft and Gault, MDRD, and Wright equations in Oncology patients with renal impairment.

Authors:  O O Faluyi; S P Masinghe; R L Hayward; S Clive
Journal:  Med Oncol       Date:  2011-02-01       Impact factor: 3.064

2.  Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment.

Authors:  Kevin R Kelly; Nashat Gabrail; Steven Weitman; John Sarantopoulos; Anthony J Olszanski; William Edenfield; Jurgen Venitz; Guru Reddy; Allen Yang; Steven J Hasal; A Craig Lockhart
Journal:  Cancer Chemother Pharmacol       Date:  2016-09-16       Impact factor: 3.333

3.  Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907.

Authors:  Stuart M Lichtman; Constance T Cirrincione; Arti Hurria; Aminah Jatoi; Maria Theodoulou; Antonio C Wolff; Julie Gralow; Daniel E Morganstern; Gustav Magrinat; Harvey Jay Cohen; Hyman B Muss
Journal:  J Clin Oncol       Date:  2016-01-11       Impact factor: 44.544

Review 4.  GFR Measurement and Chemotherapy Dosing in Patients with Kidney Disease and Cancer.

Authors:  Blaithin A McMahon; Mitchell H Rosner
Journal:  Kidney360       Date:  2020-01-13

5.  Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.

Authors:  Maria De Santis; Joaquim Bellmunt; Graham Mead; J Martijn Kerst; Michael Leahy; Pablo Maroto; Iwona Skoneczna; Sandrine Marreaud; Ronald de Wit; Richard Sylvester
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

6.  Detection of early renal injury in children with solid tumors undergoing chemotherapy by urinary neutrophil gelatinase-associated lipocalin.

Authors:  Mohamed A Almalky; Sheriefa A Hasan; Tamer H Hassan; Doaa A Shahbah; Mohamed A Arafa; Naglaa A Khalifa; Rasha E Ibrahim
Journal:  Mol Clin Oncol       Date:  2015-08-31

7.  Cancer and renal insufficiency results of the BIRMA study.

Authors:  N Janus; V Launay-Vacher; E Byloos; J-P Machiels; L Duck; J Kerger; W Wynendaele; J-L Canon; W Lybaert; J Nortier; G Deray; H Wildiers
Journal:  Br J Cancer       Date:  2010-11-09       Impact factor: 7.640

8.  Use of cystatin C and serum creatinine for the diagnosis of contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography at an oncology centre.

Authors:  Joao Italo Fortalesa Melo; Rubens Chojniak; Debora Helena Costa Silva; Jose Carlos Oliveira Junior; Almir Galvão Vieira Bitencourt; Diego Holanda Silva; Marcos Duarte Guimarães; Hernandes Cerqueira Souza Silva; Denis Guilherme Teixeira Dias; Winglison Carli Rodrigues; Ellen Luzia Brancucci; Barbara Martins Soares Cruz; Beatriz Nunes Schiavon; Juliana Luz Passos Argenton; Margareth Arrivabene Camporini; Adriana Zocchio
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

9.  Prevalence of renal insufficiency in elderly cancer patients in a tertiary cancer center.

Authors:  Lucíola de Barros Pontes; Yuri Philippe Pimentel Vieira Antunes; Diogo Diniz Gomes Bugano; Theodora Karnakis; Auro Del Giglio; Rafael Aliosha Kaliks
Journal:  Einstein (Sao Paulo)       Date:  2014-09

10.  Importance of antiresorptive therapies for patients with bone metastases from solid tumors.

Authors:  Draupadi B Talreja
Journal:  Cancer Manag Res       Date:  2012-09-11       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.